We covered ESMO conference for the client specifically focusing on PD-1 safety / efficacy data, primary endpoints, charts, poster takeaways, competitor moves and custom strategies - delivering real-time intel to sharpen client’s business edge.
Identified key sessions aligned with client’s interests: As a starting point, we registered for the ESMO conference, held in October. The client had shared the key focus on PD-1 inhibitor antibodies targeting solid tumors. Our team screened all ESMO 2025 abstracts, then shortlisted the posters focused on PD-1 targeted antibodies for solid tumors. Based on the client priorities, we further categorized these abstracts into high, mid and low priority.
Captured data, presentations and key discussions:For high-priority abstracts, our team attended the full sessions, recorded everything, and delivered complete coverage with executive summaries, key clinical findings and business impact breakdowns. We captured the brief titles and the results published for abstracts falling under mid priority. For the low priority abstracts, we only captured the titles. This tiered approach ensured client resonance with the level of insight, further turning raw data into actionable intelligence.
Deep analysis with strategic implications:In the high priority abstracts, we captured the safety data, efficacy data as well as primary end points on various clinical studies focusing on PD-1 inhibitors for solid tumors. We presented detailed tables and charts along with key takeaways for each poster in that category. This gave the client real time understanding of the competitor focus areas based on the results achieved in these studies. Our team also provided customized strategies to the client to bring positive impact to their business.
Following this conference coverage, the client expanded the scope to our full Competitive Intelligence Suite, demonstrating trust in our ability to deliver pipeline-aligned insights beyond initial requirements.
